CD8A and neoplasm: Moreover, butyrate can enhance the response to immune checkpoint blockade (ICB) in CRC patients by triggering the expression of DNA binding 2 (ID2) inhibitor, which regulates IL‐12 signalling to promote the proliferation and anti‐tumour effects of CD8+ T cells.18